glp-1 analog drugs Dosage of analogues Table 3 from Glucagon-Like Peptide-1

In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)

Last month, Lilly announced that orforglipron, an orally available GLP-1 treatment, significantly lowered blood glucose levels in patients with type 2 diabetes

Researchers reported 75 ADRD cases among GLP-1 users over a mean follow-up of 2.22 years, compared with 639 ADRD cases among other GLD users over mean follow-up of 3.74 years

Be sure to include fruits, vegetables, whole grains, lean protein, and low-fat dairy in your diet

Specially formulated to support patients on GLP-1 therapies and other low-calorie diets

doi: 10.1210/clinem/dgab722 38 WillardFSDourosJDGabeMBShowalterADWainscottDBSuterTMet al